Oncologist Shares Lessons Learned From CAR T-Cell Therapy in ALL – AJMC.com Managed Markets Network
|
Oncologist Shares Lessons Learned From CAR T-Cell Therapy in ALL
AJMC.com Managed Markets Network Furthermore, toxicity is a significant concern with CAR T-cell therapies; severe neurotoxicity has been observed, though the mortality rate for these adverse events remains low, at around 2% to 3% across the approximately 230 patients studied so far … |
